1 Title page

2 3	Molecular and Proteomic Profiles of Radioiodine Refractory Papillary Thyroid Cancer
	Durania - Aida, Durata - misa & DD DTC
4 r	Running title: Proteomics & RR-PTC
5	
6	Author Hanqing Liu ^{1, #} , Jiaxi Wang ^{1, #} , Yaoting Sun ^{2, 3, 4, #} , Yan Zhou ^{2, 3, 4, #} , Pingping Hu ^{2, 3, 4} , Lu Li ^{5, 2} , Dan
7	Yang ⁶ , Deguang Kong ¹ , Zhiliang Xu ¹ , Yi Zhu ^{2, 3, 4} , Tiannan Guo ^{2, 3, 4, *} , Chuang Chen ^{1, *}
8	Yang °, Deguang Kong °, Zhiliang Xu °, Yi Zhu 2,5, °, Tiannan Guo 2,5, °, *, Chuang Chen °, *
9	
10	Addresses
11	¹ Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan University
12	at Jiefang Road 238, Wuhan 430060, China.
13	² School of Medicine, Westlake University, Hangzhou 310024, Zhejiang Province, China.
14	³ Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine,
15	Hangzhou 310024, Zhejiang Province, China.
16	⁴ Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou
17	310024, Zhejiang Province, China.
18	⁵ College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310024, China.
19	⁶ Department of Cardiology, the Second Affiliated Hospital of Chongqing Medical University,
20	Chongqing 400010, China.
21	
22	# Equal contribution.
23	
24	* Correspondence:
25	Prof. Chuang Chen, M.D.,
26	Department of Thyroid and Breast Surgery,
27	Renmin Hospital of Wuhan University,
28	Wuhan University at Jiefang Road 238, Wuhan 430060, RP China.
29	Tel: +86(0)27 88041911; Fax: +86(0)27 88041911, Email: chenc2469@whu.edu.cn.
30	
31	Prof. Tianna Guo, Ph.D.,
32	Westlake Laboratory of Life Sciences and Biomedicine,
33	School of Medicine,
34	Westlake University (Yunqi Campus) at No. 18 Shilongshan Rd., Hangzhou 310024, PR China,
35	Tel: +86(0)571 8688 6859; Fax: +86(0)571 8688 6859; Email: guotiannan@westlake.edu.cn.

37 Abstract and keywords

38 Abstract:

39 Background: Despite the generally favorable prognosis of papillary thyroid cancers (PTCs) following thyroidectomy and potential radioactive iodine (RAI) therapy, approximately one-third of patients 40 41 experiencing recurrence and metastasis eventually develop resistance to RAI, leading to a poor outcome. 42 However, the mechanisms underlying RAI-refractoriness remain elusive. The present study aimed to 43 assess the molecular and proteomic characteristics of RAI-refractory PTC (RR-PTC) to gain a deeper 44 understanding of this condition.

45 Methods: The medical records at our institution were reviewed for the selection and grouping of RR-46 PTC patients and RAI-sensitive controls. RR-PTC patients were divided into three subgroups: 47 continuous RAI uptake (ID), loss of uptake at the first I-131 treatment (iDF) and RAI uptake lost 48 gradually (iDG). Proteomic profiling and targeted next-generation sequencing were performed on 49 formalin-fixed paraffin embedded primary lesions. The incidence of gene mutations and fusions was

50 compared across groups. Bioinformatic analysis was subsequently conducted to identify the differentially

- 51 expressed proteins and enriched pathways. The correlation of protein expression and gene variances was 52 assessed.
- 53 Results: A total of 48 PTC patients with recurrence and/or metastasis were included. The expression
- 54 profiles of the RR-PTC and control groups were similar. In the subgroup comparison, enriched pathways

related to MAPK and TNF signaling were associated with negative I-131 uptake and tumor tolerance 55

- with positive I-131 uptake. The $BRAF^{V600E}$ mutation was less common in the ID group, whereas the TERT 56
- 57 promoter mutation was more common in the iDF group. NCOA4-RET fusion was more common in the

58 ID group. In addition, four proteins were dysregulated in BRAF-mutated PTCs.

59 Conclusion: The present study constructed the first proteomic profile of RR-PTC. The proteins and 60 pathways identified in the analysis may be promising biomarkers and drug targets. Gene alterations and

- 61 fusions can aid in the early diagnosis of RR-PTC.
- 62

63 Keywords: thyroid carcinoma, radioactive iodine, refractoriness, proteomics, NGS, RET/PTC3.

- 64
- 65

1 Introduction 66

Thyroid cancer ranks eighth among female malignancies¹. The incidence of this disease has increased 67 threefold or greater during the past four decades in many countries ²⁻⁴. Papillary thyroid cancer (PTC) is 68 the most common histological type and accounts for 70-96% of all thyroid cancers ^{4,5}. Most patients with 69 70 PTC achieve complete remission after undergoing lobectomy or total thyroidectomy and neck dissection. 71 However, approximately half of PTC patients present with aggressive tumor behaviors, such as tumor invasion into perithyroidal tissues, aggressive histology, vascular invasion, multiple lymph node 72 metastases, and distant metastases ^{6.7}. These patients have an intermediate or high risk of recurrence and 73 74 are thus considered or recommended for postsurgical radioactive iodine (RAI) therapy ⁸. Unfortunately, 75 one to two-thirds of patients in this subset ultimately develop RAI-refractoriness (RAIR), especially those with a high risk of recurrence ^{9,10}. RAI therapy barely improves patient prognosis under these 76 conditions. The 10-year survival rate of patients with RAI-refractory PTC (RR-PTC) has decreased to 77 78 20-65%, and their life expectancy has substantially decreased 10,11 .

79 Currently, the diagnosis of RR-PTC depends on an I-131 whole-body scan (WBS) and evidence of 80 regional and/or distant metastatic lesions⁸. Owing to the high affinity of thyroid follicular cells for iodine, 81 radioactive isotopes are concentrated in PTC cells and exert a tumor-killing effect by emitting β -rays. In 82 most cases, two or more I-131 WBSs are required for the final confirmation of RAIR. Given that the routine time interval between two I-131 WBSs is six months ¹², the diagnosis of RAIR is made nine to 83 twelve months after the initial surgery. The time lag postpones the start of systemic therapy (e.g. multi-84 85 kinase inhibitors, MKIs) and/or local treatments. Early identification of the RAIR can avoid unnecessary 86 RAI therapy and thus improve patient prognosis by shifting to alternative treatments.

87 Many studies have focused on the early diagnosis of RAIR cancer during the past decade. Positron 88 emission tomography (PET) is a valuable tool. Previous studies have shown that the "flip-flop" 89 phenomenon of I-131 WBSs and PET (negative I-131 and positive F-18-FDG uptake) is indicative of the RAIR¹³. In addition to radiological tools, *BRAF*^{V600E} and *TERT* promoter mutations can also contribute 90 to the diagnosis of RAIR. The $BRAF^{V600E}$ mutation can impair the expression of the sodium iodide 91 symporter (NIS) and promote malignancy in tumor cells ^{14,15}. A previous retrospective study revealed 92 93 that a combination of BRAF^{V600E} and TERTp mutations, which presented in one-fifth of the PTC cohort, 94 strongly predicts RR-PTC at a positive predictive value of 97.4%¹⁶. However, for approximately 80% 95 of patients without the genetic duet, the negative predictive value was only 47.6%. A subsequent study revealed that 52.9% of patients with the genetic duet presented with RAIR¹⁷. Generally, several factors, 96 97 including high cost and unsatisfactory accuracy, have restricted the use of these diagnostic tools in 98 clinical practice. Currently, the four criteria for RAIR differentiated thyroid cancer (DTC) are still based 99 on the I-131 WBS and additional evidence for recurrence or metastasis⁸. In addition, although the RAIR is related to gene alterations in clinical studies ^{18,19}, the mechanism underlying refractoriness is not fully 100 understood. For example, the NIS protein was not necessarily downregulated, as the above article 101 revealed. It can be upregulated and exert a non-pump pro-tumorigenic effect on thyroid cancer cells ^{20,21}. 102 Proteins are important participants in tumorigenic processes and dedifferentiation. Mass-based 103 104 proteomics is a rapidly developing technique that facilitates comprehensive investigations into molecular 105 activities and biological processes involved in cancer initiation and progression. Lots of diagnostic 106 biomarkers and therapeutic targets in clinical practice are based on proteins. Proteomics has been widely used to reveal the cellular activities of thyroid cancer cells since its first appearance ^{22,23}. Recently, 107

108 proteomics has been used in several areas of thyroid cancer research, including discrimination of benign and malignant nodules, subtype identification, and risk stratification ^{24,25}. During the past two years, Sun 109 et al. constructed a comprehensive thyroid tissue proteomic spectral library and distinguished between 110 111 follicular adenomas and follicular thyroid carcinomas²⁶. In addition, Shi et al. plotted the multi-omic 112 atlas of medullary thyroid carcinoma via the proteomic technique ²⁷. The proteomic profile of RR-PTC 113 has not yet been revealed, which may help improve the early diagnosis of RR-PTC in clinical practice 114 and understand the mechanism of RAIR. This study aimed to construct 23-gene panel-based molecular and proteomic profiles of RR-PTC and 115 to identify promising biomarkers related to RAIR, which could aid in early identification and drug target 116 117 selection.

118

119 2 Results

120 2.1 Patient cohort

121 Based on the inclusion and exclusion criteria in the Patients and Methods section, forty-eight patients 122 with locoregional or distant metastatic PTCs were recruited for our study (Table 1). The average age of 123 all patients was 38.4 ± 12.69 years, and the patients in the RR-PTC group were slightly older than those in the control group (P = 0.421). Interestingly, all five patients ≥ 55 years old were in the RR-PTC group. 124 125 Although females were more common in the control group (72.7% vs. 54.1%, P = 0.319), the difference 126 was not significant. In addition, no differences were found in the tumor diagnosis, smoking status or 127 alcohol consumption, body mass index or the incidence of concomitant thyroid diseases between the two 128 groups.

129 The histopathological subtypes of PTC were identically distributed between the two groups. No 130 significant differences were found in terms of tumor size, multifocality or bilateral lesions. The incidence of extrathyroidal extension (ETE) was greater in the RR-PTC group with marginal statistical significance 131 132 (P = 0.095). Owing to differences in age and ETE, T2-4 categories were more common in patients with RR-PTC (91.9% vs. 63.6%, P = 0.039). The presence of lymph node metastatic lesion (LNM) was similar 133 in the two groups, but distant metastasis was much more common in the patients with RR-PTC (56.8% 134 135 vs. 9.1%, P = 0.006). Consequently, higher AJCC stages were observed in RR-PTC patients (P = 0.001). Compared with patients in the control group, patients in the RR-PTC group received larger doses of I-136 131 after the initial resection of primary tumors. Notably, all six patients who died were in the refractory 137 138 group.

139

2.2 Molecular profile of PTCs correlated with I-131 resistance 140

141 A total of 23 genes were sequenced (Sup table S1). Four genes were found to harbor driver mutations 142 (Table 2). The $BRAF^{V600E}$ mutation was identified in 25 samples (56%), with no significant difference

- between the RR-PTC group and the control group (54.3% vs. 60.0%, P = 1.000). All six samples with 143
- 144 TERTp mutations (17.1% vs. 0%, P = 0.312) were in the RR-PTC group. In addition, RET and TP53

145 mutations were found in one and two patients, respectively. RAS mutations, including HRAS, KRAS and NRAS, were not detected in any samples. In addition, four kinds of gene fusions were found, namely, 146 eight samples with NCOA4-RET, two with CCDC6-RET, three with ETV6-NTRK3 and one with STRN-147 148 ALK. Fusions were more frequent in the control group (28.6% vs. 40.0%, P = 0.700), whereas RET-149 related fusions were almost equally distributed (22.9% vs. 20.0%, P = 1.000). However, no significant 150 differences in the expression of these genes were found between the two groups.

The forty-five samples were then divided into four subgroups. The BRAF^{V600E} mutation was less 151 common in the continuous RAI uptake (ID) group (11.1%, P < 0.05), whereas the *TERTp* mutation was 152 153 more frequent in the loss of uptake at the first I-131 treatment (iDF) group (33.3%, P < 0.05). Notably, 154 NCOA4-RET fusion was more common in the ID group (44.4%, P < 0.05).

155 The present study further evaluated the associations between gene variants and I-131 uptake. The 156 samples in the ID and RAI-sensitive PTC (Id) groups were categorized as positive for I-131 uptake. 157 $BRAF^{V600E}$ mutation was more frequent in the negative I-131 uptake group with statistical significance 158 (69.2% vs. 37.8%, P = 0.039). The incidence of *TERTp* mutations was also greater in this group (19.2%) 159 vs. 5.3%, P = 0.222). In contrast, fusions were more common in the positive uptake group (23.1% vs. 42.1%, *P* = 0.206). 160

161 The distribution of gene variants with unknown clinical significance was also assessed (Sup table S2). 162 Four variants were subjected to nonparametric tests after those with a frequency < 3 were filtered out. 163 The four mutations were located on ATM (c.1236-2A>T), PTEN (c.402G>A) and RET (c.2071G>A and 164 c.2671T>G). Three variants were more common in the RR-PTC group, except for PTEN c.402G>A, although the difference was not statistically significant. In subgroup analysis, the incidence of PTEN 165 c.402G>A was greater in the ID group (22.2%, P < 0.05). In addition, *PTEN* c.402G>A was associated 166

167 with positive I-131 uptake with marginal significance (0% vs. 15.8%, P = 0.068).

168

2.3 Overview of the proteomic profiling 169

170 To profile the proteomic characteristics of RR-PTC, we collected 168 tissue slides from 73 patients. A 171 total of 9769 proteins were identified (Sup figure 1A), which indicated the high quality of our data. Since the number of proteins identified in all the samples exceeded the threefold interquartile range (≤ 1614), 172 no sample was excluded from subsequent analysis. The principal component analysis (PCA) plot 173 174 annotated by batch groups indicates no observable batch effect during data acquisition (Sup figure 1B). 175 Although samples were well resolved by their site, tumor tissues mixed with little difference but negative 176 lymph nodes were clustered (Sup figure 1C). The R values of correlation analyses exceeded 0.97 in both 177 intra-batch and inter-batch tests, indicating high technical stability across the data acquisition (Sup figure 178 1D&E). Overall, no observable batch effect was detected (Sup figure 1F).

179 Next, the raw files were converted to an expression matrix. We applied a filtering criterion to select 180 proteins with missing values less than 50%. These 7406 filtered proteins were then subjected to data 181 normalization and outlier substitution (Sup figure 2A-C). After ID conversion, an expression profile 182 encompassing 7394 proteins across 168 samples was compiled (Sup figure 2D). As indicated by the 183 ESTIMATE algorithm, the median tumor purity was 76.2% (Sup figure 2E), indicating the reliability of 184 our dataset for further analysis.

185 The global proteomic profiles of the original PTC lesions were subjected to dimensionality reduction 186 to evaluate the clustering of the samples. The area covered by the samples represented similarity within

a group. The RAI-sensitive samples were more tightly clustered than the RR-PTC samples (Figure 1A). 187 188 The overlap of the two groups might be explained by the similarity between tumor tissues and the intrinsic heterogeneity of RR-PTC samples. To minimize potential heterogeneity, we furtherly divided 189 190 RR-PTCs into three subgroups (iDF, iDG and ID) as described in the patients and tissue selection section. 191 The diversity of the ID group was the lowest among the three subgroups, while the diversity of the RAI 192 uptake lost gradually (iDG) group was the highest (Figure 1B). Interestingly, when labeled with the BRAF^{V600E}-mutation status, samples in the two groups were separately clustered (Figure 1C). 193

194 Subsequently, 107 differentially expressed proteins (DEPs) with P values < 0.05 and absolute fold 195 change (FC) > 1.414 were identified via the multiple linear regression algorithm (Figure 1D). Eighty-196 nine proteins were upregulated in the RR-PTCs, whereas the remaining eighteen proteins were 197 downregulated. The top upregulated protein in the RR-PTCs was KRT71 (keratin, type II cytoskeletal 198 71, $\log_2 FC = 1.422$). Interestingly, the top downregulated protein also belonged to the keratin family (keratin, type I cytoskeletal 16, KRT16, $log_2FC = -0.955$), which suggested the potential involvement of 199 200 the cytoskeleton in the progression of RAIR. Samples were clustered unsupervisely based on the 107 201 DEPs and then labeled with clinicopathological features (Figure 1E). The borders of the 202 clinicopathological labels were generally indistinct. However, the thyroid differentiation score (TDS) 203 and extracellular signal-regulated kinase (ERK) score were correlated with the groups to some extent 204 (Figure 1F). The TDS was lower in the RR-PTC group, which could indicate poorer differentiation (P =205 0.288). Conversely, the ERK score was greater in the RR-PTC group (P = 0.215). Unfortunately, none 206 of these scores reached statistical significance.

Gene set enrichment analysis (GSEA) based on the Reactome database revealed 64 pathways with 207 statistical significance (Sup figure 3A). Twenty-nine pathways with positive normalized enrichment 208 209 scores (ESs) were unregulated in RR-PTC samples. The pathway with the greatest increase was gamma 210 carboxylation hypusine formation and arylsulfatase activation (nES = 1.687). In addition, Akt 211 phosphorylates targets in the cytosol was also upregulated (nES = 1.552). The remaining 39 pathways 212 were downregulated. Regulation of mRNA stability by proteins that bind Au-rich elements was mostly 213 suppressed for RR-PTCs (nES = -1.960). Notably, RAS processing was also downregulated (nES = -214 1.728). The Kyoto Encyclopedia of Genes and Genomes (KEGG) database was also used for the 215 annotation of pathways closely related to oncogenesis and dedifferentiation (Sup figure 3B). P53 signaling was significantly enriched (nES = 1.5440, P = 0.0136). Interestingly, the MAPK signaling 216 217 pathway showed a slight positive correlation with RR-PTCs (nES = 1.2623, P = 0.1642). The gene set 218 variation analysis (GSVA) results supported the above results (Sup figure 3C).

219 A previously published study assessed the transcript profiles of RR-PTC via a gene microarray ²⁸. The 220 DEPs identified in the present study were assessed via this profile to determine whether they were robust 221 in another cohort. Ninety-nine of the 107 DEPs were identified in this cohort, and only three of them 222 were dysregulated (Sup figure 3D). BET1 and C11orf96 were downregulated in the RR-PTC group 223 (BET1 median: 6.534 vs. 6.105, P = 0.032; C11orf96 median: 7.338 vs. 7.028, P = 0.032). The expression 224 of SLC4A9 was greater in the RR-PTC group (median: 5.216 vs. 5.392, P = 0.045). Notably, the 225 regulation direction of BET1 and SLC4A9 was consistent with the results of the present study, whereas 226 C11orf96 was oppositely expressed in the two analyses. GSVA based on the Reactome and KEGG 227 databases revealed two differentially downregulated pathways (N-glycan antennae elongation and GAB1 228 signalosome), none of which were enriched in our study (Sup figure 3E&F).

229 To assess the spectral change in RR-PTC, the Id, ID and iDF subgroups were defined as having low, intermediate and high severity, respectively. A total of 403 proteins with significance difference in 230

perpetuity. All rights reserved. No reuse allowed without permission.

analysis of variance were divided into six clusters (Sup figure 4). In two clusters, 160 proteins were monotonically regulated (Sup figure 5A). Collagen biosynthesis and modifying enzymes were significantly enriched in Metascape (Sup figure 5B). In addition, regulation of protein autophosphorylation and regulation of extrinsic apoptotic signaling pathway were also associated with the severity of RR-PTC. The results were supported by the ingenuine pathway analysis (IPA) database (Sup figure 5C).

237

238 2.4 Proteomic biomarkers and pathways associated with I-131 uptake

239 For analysis of proteomic biomarkers and the underlying mechanisms for the loss of I-131 uptake in PTC, two subgroups, ID and iDF, were included in the subsequent analysis of this section. The ability of 240 241 these two groups to take up I-131 was completely different at the first radiotherapy. The demographic 242 and clinicopathologic characteristics of the two groups were roughly comparable (Sup table S3). No 243 significant differences were observed in histopathological features, tumor staging or risk stratification. 244 Interestingly, four patients in the iDF group drank alcohol and/or smoked, while no individual in the ID 245 group reported these behaviors (P = 0.033). In addition, the patients in the iDF group had greater weights than their counterparts (P = 0.010). Since the diagnosis of RR-PTC in the ID group required multiple 246 247 rounds of I-131 treatment, the cumulative dose of I-131 was inevitably greater than that in the iDF group 248 (P = 0.001).

- Although the ID and iDF groups overlapped with each other to some extent, a total of 145 DEPs were identified with *P* values < 0.05 and absolute FC > 1.414 (Figure 2A&B). Ninety-five proteins were upregulated in the ID group, whereas the remaining 50 proteins were highly expressed in the iDF group. The 145 DEPs could barely separate the two groups. The TDS was greater in the ID group, whereas the ERK score was lower. However, none of these scores reached statistical significance (Figure 2C&D).
- 254 Pathway enrichment analysis was then conducted. Only seven pathways in the KEGG database were 255 significantly enriched. Among the seven pathways, glutathione metabolism and Notch signaling were 256 enriched in the ID group whereas TGF-beta signaling and ECM receptor interaction were enriched in the 257 iDF group (Figure 2E). Fifty-one pathways in the Reactome database were significantly enriched. The top enriched pathway was "activated TAK1 mediates P38 MAPK activation" with an nES of 1.9182 258 259 (Figure 2F). In addition, several MAPK-related pathways, including ERK/MAPK targets and prolonged 260 ERK activation events, were correlated with positive I-131 uptake. In addition, TNF signaling and 261 glutathione conjugation were associated with positive I-131 uptake.
- 262 The results of pathway enrichment were then assessed via GSVA. Sixty-three pathways were 263 significantly enriched and 18 of these pathways overlapped with the GSEA results (Figure 3A). After the 264 associations between pathways and tumor progression were evaluated, sixteen pathways were found to 265 play roles in the loss of I-131 uptake in PTC, eleven of which overlapped with the GSEA results (Figure 266 3B). Six pathways were closely related to MAPK signaling. Three pathways are associated with 267 transforming growth factor- β activated kinase 1 (TAK1) signaling. In addition, one pathway was correlated with both MAPK and TAK1 signaling. The other six pathways involved glutathione 268 269 metabolism, TNF signaling and MET proto-oncogene (MET) signaling. The expression of proteins 270 involved in these thirteen pathways was compared between the RAI-positive and RAI-negative groups. 271 Proteins with an absolute FC > 1.2 were displayed (Figure 3C).
- 272 The results of our proteomic profile were validated with a transcriptomic profile of RR-PTCs

273 (GSE151179). The samples in GSE151179 were categorized as ID or iD based on their I-131 uptake. 274 The iD group was not subdivided into iDF or iDG since the information was not provided. A linear 275 regression algorithm identified three common differentially expressed genes (DEGs) (Sup figure 6A). 276 However, the regulatory direction was completely different. In the proteomic profile, MYH7 was up-277 regulated, whereas in the transcriptomic profile, its expression was greater in the iD group. S100B and 278 UXT also exhibited inverse changes in the two profiles. Only MYH7 significantly differed according to 279 the nonparametric test (P = 0.035). GSVA revealed five common pathways (Sup figure 6B), and the 280 direction of the change in expression was consistent between the two profiles. Notably, three TAK1-281 associated pathways were significantly enriched. All genes involved in the 16 selected pathways and 282 these five common pathways were tested. Only three genes were differentially expressed between the 283 two groups. PI4K2B and PIK3R4 participate in the synthesis of PIPs at the early endosome membrane, 284 and CEACAM8 is involved in fibronectin matrix formation (Sup figure 6C).

Immune analysis based on the ssGSEA matrix revealed an abundancy of memory B cell and a deficiency 285 286 of macrophage and immature T cell in the ID samples (Sup figure 7A). Notably, eosinophils were more 287 abundant in RAI-sensitive samples compared to RR-PTCs. However, immunohistochemistry results did 288 not show any statistically significant differences (Sup figure 7B).

289

290 2.5 Proteomic biomarkers and pathways for different responses to positive I-131 uptake

291 The data of twenty-one patients in the ID group and the Id group (or control group) were compared to determine the potential mechanisms underlying the different responses to positive I-131 uptake in PTC 292 293 patients. The baseline characteristics of the two groups were compared (Sup table S4). No significant 294 differences in demographic or tumor features were found, except for a greater incidence of ETE in the 295 ID group (P = 0.035). More distant metastases were found in the ID group (80% vs. 9.1%, P = 0.002), 296 and consequently, the disease stages were greater (P < 0.001). According to the criteria of the ID group, 297 the cumulative I-131 dose was inevitably greater (P < 0.001).

298 Similar to the previous comparison, the two groups could be distinctly separated from each other (Figure 299 4A). Twenty-one samples were roughly divided into two groups with 125 DEPs identified via the multiple linear regression algorithm (Figure 4B&D). No significant differences were found in the TDS, 300 301 ERK score, T cell infiltration score (TIS), immune infiltration score (IIS) or immune cytolytic activity 302 score (CYT) (Figure 4C).

303 GSEA revealed twelve enriched pathways based on KEGG annotations. The p53 signaling pathway (P 304 = 0.0498) and mTOR signaling pathway (P = 0.0346) were both promoted in the RAI-resistant samples (Figure 4E). Interestingly, inositol phosphate (IP) metabolism was also activated in the ID group (P =305 306 0.0190). No significant difference was revealed in the MAPK signaling pathway. Forty-five pathways 307 were significantly enriched according to the Reactome annotation file. TP53-related pathways, including 308 regulation of TP53 through association with co-factors (P = 0.0260) and methylation (P = 0.0463), were 309 increased in ID samples (Figure 4F). TNF signaling (P = 0.0188) and its participant TNFR1-induced NFkappa-B signaling pathway (P = 0.0021) were both associated with RAI uptake and resistance. In 310 311 addition, the pathway "activated TAK1 mediates p38 MAPK activation" was closely related to RAI-312 resistance (P < 0.0001). An increase in IP metabolism was also detected (P = 0.0081).

GSVA based on the Reactome annotation file was conducted to verify the previous results. A total of 49 313 314 pathways were enriched with significant differences, eleven of which overlapped with previous results

perpetuity. All rights reserved. No reuse allowed without permission.

315 (Figure 3D). After the search and selection, four clusters comprising thirteen pathways were pooled for 316 subsequent analysis (Figure 3E). Eight of the thirteen pathways were also dysregulated according to 317 GSEA. A total of 39 proteins involved in TNF signaling, TAKI-related pathways, plasma lipoprotein 318 remodeling and IP-related pathways were identified with an absolute FC > 1.2 (Figure 3F).

319 The expression levels in the transcriptomic profiles of the ID and Id groups were then compared for

320 validation. Only PGS1 was downregulated in the ID group (median: 6.080 vs. 6.456, P = 0.012; Sup

figure 6D), which was consistent with the proteomic data. According to the pathway analysis, only GAB1

signalosome was significantly decreased in the ID group (P = 0.012, Sup figure 6E). However, none of the genes in the GAB1 signalosome were differentially expressed between the two groups. Among those involved in the above thirteen pathways, three genes (MAPKAPK2, NFKB1 and PLKHA6) were downregulated in the ID group, in contrast to the expression pattern observed in our proteomic profile

- 326 (Sup figure 6F).
- 327

328 2.6 Association of gene variance and protein expression

329 The 7394 proteins were divided into 21 modules via weighted correlation network analysis (WGCNA) (Figure 5A&B). BRAF mutation was significantly correlated with seven gene modules, among which the 330 331 blue module had the highest absolute correlation coefficient (CC) (CC = 0.61, P = 8.4e-6). The most 332 prominent module associated with *TERTp* mutations was pink (CC = -0.45, P = 1.9e-3). The green-333 yellow module was closely related to the gene fusions (CC = 0.42, P = 3.7e-3) and the NCOA4-RET 334 fusion (CC = 0.32, P = 0.03). For other gene variants of unknown significance, ATM c.1236-2A>T was 335 related to the green module (CC = 0.41, P = 5.0e-3). In addition, RET c.2671T>G was closely associated 336 with the yellow module (CC = 0.50, P = 4.5e-4).

337 Three machine learning algorithms (LASSO, RF and SVM-RFE) were used to select biomarker proteins 338 from the most correlated modules of each gene mutation and fusion. Since other gene mutations were 339 generally rare (< 10%) in the present study, samples with BRAF mutation, TERTp mutation, gene fusion 340 and NCOA4-RET fusion were retained for subsequent analysis. A total of 28, 32 and 39 proteins were 341 used for model construction of BRAF mutations via the least absolute shrinkage and selection operator (LASSO) regression, random forest (RF), and support vector machine-recursive feature elimination 342 343 (SVM-RFE) algorithms, respectively, and four of these proteins were common biomarkers (Figure 5C). 344 In addition, only PTCD1 and AHCYL2 were revealed to be common biomarkers for gene fusions. 345 According to the receiver operating characteristic (ROC) curves of The Cancer Genome Atlas Thyroid 346 Cancer (TCGA-THCA) dataset, the areas under the curve (AUCs) of three genes exceeded 0.9 (Figure 5D). PTPRE had the highest accuracy (AUC = 0.93), followed by TMEM43 (AUC = 0.92) and FN1 347 348 (AUC = 0.91). According to the merged Gene Expression Omnibus (GEO) profile, the most accurate 349 gene was TMEM43 (AUC = 0.80), followed by FN1 (AUC = 0.73) and SUSD2 (AUC = 0.69). 350 Interestingly, PTPRE did not significantly differ. The AUCs of AHCYL2 for gene fusions in TCGA-351 THCA and merged GEO cohorts were 0.65 and 0.68, respectively. Disease free survival analysis revealed that dysregulation of FN1 (HR = 2, P = 0.026) and AHCYL2 (HR = 0.53, P = 0.038) was associated with 352 353 poor prognosis in patients with thyroid cancer (Sup figure 8).

To explore the potential biomarkers and pathways in case of *BRAF* mutation and wild-type *TERTp*, only BRAF-mutated and *TERTp*-unmutated samples were analyzed. A total of 184 proteins were significantly different between the RAIR-refractory and RAIR-sensitive groups (Sup figure 9A&B).

357 Metascape revealed that several pathways related to the immune response, including T cell activation,

regulation of lymphocyte activation and phagocytosis, were enriched with statistical significance (Sup 358

figure 9C). IPA results also supported these findings (Sup figure 9D). Granzyme A signaling was 359

360 downregulated in BRAF-wild-type samples, whereas neutrophil degranulation, B cell development and

- 361 phagosome formation were upregulated in BRAF-mutated TERTp-unmutated samples.
- 362

363 **3** Discussion

364 To our knowledge, the present study is the first to construct a proteomic profile of RR-PTC on primary lesions. We evaluated the differences in the expression of genes in the RAI-refractory and RAI-sensitive 365 366 samples. Three genes were potential biomarkers for RR-PTC. To minimize the intrinsic heterogeneity due to different criteria, we subdivided RR-PTC primary lesions based on the response to radiotherapy 367 368 and the presence of I-131 uptake. Proteins and potential pathways associated with these two tumor 369 behaviors were evaluated. MAPK signaling was the most commonly involved pathway. TGF-beta and 370 TAK1 signaling was revealed to be associated with the loss of I-131 uptake. In contrast, tumor necrosis 371 factor (TNF) signaling might affect cancer cell death in positive foci. Targeted deep sequencing revealed 372 that wild-type *BRAF* and *TERTp* mutation were associated with the ID and iDF phenotypes, respectively. 373 NCOA4-RET fusion was more frequent in the ID group. With respect to protein expression and gene 374 variance, four proteins were associated with *BRAF*^{V600E} mutation.

375 Many previous studies have investigated the dedifferentiation mechanism and redifferentiation targets

376 of RR-PTC. NIS is the most important transporter of iodide and is highly expressed in thyroid epithelium 377 ²⁹. Previously, researchers hypothesized that the downregulation of NIS in primary tumors contributed to the loss of RAI uptake in metastatic RR-DTC lesions ³⁰. This hypothesis was soon challenged by the 378 379 intracellular overexpression of NIS in ~70% of thyroid cancer samples ²¹. In 2018, Feng et al. reported that increased intracellular NIS could exert a non-pump pro-tumorigenic effect ²⁰. The relationship 380 between NIS expression and the RAIR has yet to be determined ^{31,32}. Owing to the methodological 381 382 limitation of proteomics, we failed to quantify NIS protein expression. However, seven molecules 383 indicating thyroid differentiation, including PAX8, TG and TPO, were identified. Although the TDS 384 tended to increase in the RR-PTC samples, the difference did not reach statistical significance. 385 Consequently, our results do not fully support that thyroid-specific proteins in primary lesions could be 386 used as diagnostic biomarkers for RR-PTC.

387 The associations between thyroid cancer and gene variants have been widely discussed. The pathway 388 most likely related to dedifferentiation and RAI refractoriness was MAPK signaling ³³. MAPK signaling 389 regulates cell proliferation, dedifferentiation and death. BRAF is an essential kinase in the cascade. The 390 $BRAF^{V600E}$ mutation has been reported to be associated with aggressive tumor behavior and poor prognosis 34,35 . Recent studies have revealed a strong correlation between $BRAF^{V600E}$ mutation and 391 negative iodine uptake 16,28 , which was confirmed by a meta-analysis 36 . The overall prevalence of *BRAF* 392 393 mutation was ~55% in our study, but ID samples were less likely to harbor BRAF mutation (~10%) than 394 other subgroups. Given that BRAF mutation can impair the expression of the NIS protein ³⁷, recurrent or 395 metastatic lesions without BRAF mutation are prone to be positive in I-131 WBSs. Interestingly, a more 396 recent study by Mu et al. revealed a lower rate of BRAF mutation in the "continuously RAI-avid but

397 RAI-refractory" group (~14%) than in the partial and gradual RAI-refractory groups ³⁸. Although few

398 studies have subdivided RR-PTC based on different criteria, we could hypothesize that ID tumors have distinct molecular features and tumorigenic mechanisms. However, it is difficult to explain the high 399 400 prevalence of *BRAF* mutation in the Id group in our study, which was not consistent with many previously published articles ^{31,38,39}. Some studies have reported no significant correlation between *BRAF* status and 401 402 RAI uptake ^{40,41}. It was assumed that clinical pathways in different countries/regions and patient selection

403 protocols contributed to the diverse observations to some extent ³⁵.

- In addition, *TERTp* mutation is a promising predictive factor for the RAIR. The prevalence of this 404 405 mutation was lower than that of the BRAF mutation, but patients harboring TERTp mutations had poorer prognoses and greater mortality ⁴². Liu *et al.* reported that the genetic duet of *BRAF* and *TERTp* mutations 406 407 robustly predicted the loss of RAI avidity in PTCs with a high positive predictive value (97.4%)¹⁶. 408 However, the negative predictive value was lower than 50%, which limits its utility in clinical practice. 409 Subsequent studies have shown similar but somewhat different results ¹⁷. The genetic duet could predict 410 RAIR with a positive predictive value barely higher than 50%. A recent study from Shanghai revealed that TERT accelerated BRAF-mutated thyroid cancer dedifferentiation and progression by regulating 411 ribosome biogenesis ⁴³. Our study also revealed a greater rate of *TERTp* mutation in the RR-PTC group. 412 413 Interestingly, TERTp mutation was significantly more frequent in iDF samples, indicating its strong 414 association with the loss of RAI uptake. This observation was in accordance with a previously published article ³⁸. Since all six *TERTp*-mutated samples harbored the $BRAF^{V600E}$ mutation, we did not test the 415 416 combined efficacy of the two mutations.
- 417 Of interest, our study revealed a significantly greater incidence of NCOA4-RET (PTC3-RET) fusion in the ID group. This phenomenon was also observed in two studies. An Italian study revealed that fusion 418 genes (especially RET-PTC) were more common in ID (39%) than in iD (16%) and Id (13%) patients (P 419 = 0.075)²⁸. Mu's study revealed that the incidence of *RET*-fusions in the ID subgroup (~40%) was greater 420 421 than that in other RR-DTC subgroups and the Id group ³⁸. However, statistical significance was not 422 reached in the above two studies. A subsequent study from Mu's institution revealed that fusion 423 oncogenes in pediatric DTCs were associated with RAI-refractoriness (P = 0.017)⁴⁴. But *RET*-fusions 424 were not analyzed separately. The radioactive isotope is concentrated in thyroid epithelium-derived 425 tumor cells and exerts tumor-killing effect by emitting β -rays. Considering that *RET* rearrangements can activate its kinase and inhibit apoptosis via the MAPK and PI3K signaling pathways ^{45,46}, the apoptosis 426 427 triggered by radioisotope-induced DNA damage could also be impaired by *RET* alterations, especially 428 the NCOA4-RET fusion. The potential causal relationship between RET fusion and the ID phenotype has 429 not been verified in cell or animal experiments. Recent clinical studies have shown that the RET fusiondirected therapy can restore RAI avidity in patients with RR-PTC 47,48. 430
- The accuracy of gene mutations and fusions are helpful but not satisfactory. Proteomic analysis was 431 432 conducted to identify promising biomarkers related to the RAIR. Although the expression differences 433 between phenotypes were generally not obvious, some signaling pathways were significantly enriched. 434 In the comparison of the RAI-sensitive and RAI-refractory groups, P53 signaling was the pathway most 435 likely associated with the loss of iodine uptake. Although some scholars have suggested that TP53-436 mutated follicular adenomas are precursors for the dedifferentiation of anaplastic thyroid cancer ⁴⁹, few 437 studies have investigated the correlation between the RAIR and mutations in P53 signaling. At that time, 438 we assumed that the heterogeneity in RR-PTC reduced the power of the test. In the subsequent 439 comparisons of subgroups (ID vs. iDF and ID vs. Id), enriched pathways clustered into several major pathways, including the MAPK signaling and TNF signaling pathways. The MAPK pathway is strongly 440 related to thyroid cancer behaviors, and BRAF mutation impairs the expression of the NIS protein by 441

deacetylating its gene promoter histones ³⁷. MAPK inhibitors and histone deacetylase inhibitors can 442 restore iodine uptake and re-differentiate PTC cells ^{50,51}. Interestingly, our study revealed that TAK1-443 associated pathways were also correlated with that RAIR. A recent study suggested that silencing TAK1 444 445 inhibited the proliferation and migration of thyroid cancer cells via that suppression of p38 MAPK 446 signaling ⁵². We hypothesize that TAK1 is a novel potential molecular target of RAIR. The TNF signaling 447 is another pathway of interest. TNF is an important cytokine that triggers inflammation. A retrospective 448 study by Gheorghe *et al.* suggested that $TNF-\alpha$ might exert different antitumor effects in response to RAI therapy depending on the patient's immune profile ⁵³. The activation of TNF signaling might restore I-449 131 uptake and promote redifferentiation in thyroid cancer cells. Unfortunately, most proteins involved 450 451 in these pathways did not significantly differ.

- 452 Most of the molecules identified in the article were not the main regulators of their pathways. However, 453 these three proteins warrant further discussion. There are few reports of S100B in thyroid cancer, but its 454 high expression promotes cancer metastasis via interaction with P53 signaling in other glandular epithelium-derived carcinomas ⁵⁴. NFKB1 belongs to the well-known NF-kB signaling, which is closely 455 related to cancer initiation and progression. A functional polymorphism in its promoter increases the risk 456 of PTC 55. In addition, FN1 overexpression was found in aggressive thyroid cancer and promoted its 457 migration and invasion ⁵⁶. The expression of this molecule was greater in *BRAF*-mutated PTCs and was 458 459 indictive of poor prognosis 57. These proteins are associated with aggressive cancer behaviors and could 460 be promising biomarkers for RR-PTC.
- 461 The current study did not focus on the iDG group because of its high intrinsic heterogeneity, but one hypothesis could help explain the process of loss of I-131 uptake in this group. The original tumor may 462 comprise heterogeneous cancer cells with different tolerances to I-131 treatment. I-131 exerted a 463 464 selective effect on cells, and those with greater tolerance survived, which ultimately results in the 465 formation of negative uptake foci on I-131 WBSs.
- 466 Several previous studies have plotted the molecular and omic atlas of RR-DTC (Sup table S6). Sabra and Shobab independently constructed the genomic landscape for RR-DTC 58,59. Mutations in the MAPK 467 signaling pathway accounted for ~50% of oncogenic drivers, which was similar with our results. In 2020, 468 Colombo et al. constructed molecular and gene/miRNA profiles for RR-PTC 28. BRAF mutation was 469 470 more frequent in the RAI-negative RR-PTC group. Although PTCs were clearly distinguished from 471 normal thyroid tissues, no distinct expression patterns were found between RAI-refractory and RAI-472 sensitive PTCs. In general, our results were consistent with those of Colombo's study. A distinguishable 473 feature for RAIR was not found based on either the mRNA/miRNA or protein profile, regardless of 474 subclassification. The insufficient sample size may partly explain this phenomenon. One hypothesis is 475 that the RAIR occurs during recurrence and metastasis. The hypothesis, however, is not convincing in 476 the presence of some RAI negative lesions at the first I-131 treatment. Another competing hypothesis is 477 that the underlying mechanisms of the RAIR are trivial and are covered by the heterogeneity of other 478 tumor behaviors. More homogenous samples and proper subclassification are needed to eliminate 479 confounding effects and uncover the underlying mechanisms involved. Two precursor studies provided novel insights into the proteomic expression of RR-PTC but were limited by small sample sizes and the 480 lack of primary tumors 60,61. 481

482 The current study has several shortcomings. First, although the medical records of more than ten 483 thousand patients were reviewed thoroughly by independent researchers, the intrinsic nature of this single-center, retrospective study and the relatively small sample size limit the generalizability of our 484 485 conclusions. In addition, the lack of Benjamini-Hochberg correction for differential expression analysis

486 undermined the reliability of the results. In addition, due to the lack of previous proteomic profiles, potential protein biomarkers were tested with several external transcriptomic profiles. The consistency 487 of expression across mRNAs and corresponding proteins is debatable ²⁷. Moreover, FTC samples and 488 489 metastatic lesions were excluded from the present study because of the small sample size and potential 490 histopathological heterogeneity. The potential biomarkers and mechanisms were not verified with in vivo 491 experiments. The above observations of our study could be confirmed with multicenter large-sample 492 proteomic profiling. Cell and animal experiments could help verify our results. 493 In conclusion, a proteomic profile based on RR-PTC primary lesions was constructed for the first time 494 in the present study. Our current work improves the molecular and biological understanding of RR-PTC, 495 which could enlighten future preclinical and clinical studies toward molecule-guided treatment. The 496 dataset created in this study could serve as an important resource for further investigations of RR-PTC 497 biology and therapeutic targets.

498

499 **4** Patients and Methods

500 4.1 Study design and ethics approval

501 This retrospective, case-control study was conducted at Renmin Hospital of Wuhan University. The 502 Institutional Ethical Committee of the hospital reviewed and approved the study design (No. 503 WDRY2021-K032). The requirement for obtaining informed consent from the involved patients was 504 waived due to the retrospective nature of the study. The study was conducted in accordance with the Declaration of Helsinki 62. The study was performed in accordance with the STROBE checklist for case-505 506 control study (version 4).

507

508 4.2 Patient and tissue selection

509 The medical records of patients who were diagnosed with thyroid cancer at our tertiary center from Jan. 1st, 2016 to Dec. 30th, 2022 were reviewed (Figure 6A). Patient demographic and clinicopathological 510 511 characteristics, laboratory test results and radiological results were collected by two researchers and 512 independently evaluated. During the initial screening, patients who a) had incomplete medical records 513 and b) did not undergo I-131 WBS were excluded. In the second round of assessment, histopathological 514 data and radiological images, including chest computed tomography (CT), cervical magnetic resonance 515 imaging (MRI), whole-body bone scanning and positron emission tomography (PET), were used to 516 evaluate local and distant metastasis at the first admission for surgery. Patients without cervical or distant 517 metastasis at diagnosis were excluded from the subsequent evaluation. Patients with RAI uptake limited 518 to thyroid bed and disease remission were also excluded. In the final assessment, RAI uptake was 519 determined by I-131 WBSs or I-131 single photon emission computerized tomography (SPECT). A total 520 of 73 patients were identified to have locoregional or distant metastasis, which was confirmed by 521 radiological, cytopathological or histopathological solid evidence. Patients with primary lesions not 522 resected in our center or other histopathological types other than PTC were also excluded from further

523 statistical analysis. Finally, forty-eight PTC patients with locoregional and/or distant metastasis were 524 included in this study and their primary tumor samples (one sample from each patient) were used for 525 subsequent analysis.

526 The included patients were then divided into two groups based on their response to RAI treatment: RAI-527 sensitive (RAI uptake positive and disease remission, Id) and RAI-refractory (disease persistence, Figure 528 6B). RAI refractoriness was identified in accordance with the 2015 American Thyroid Association (ATA) 529 guideline⁸. Briefly, patients with metastatic lesions that a) did not ever concentrate RAI, b) lost the ability 530 to concentrate RAI after previous evidence of RAI avidity, and c) concentrated in some lesions but not 531 in others were considered to have negative RAI uptake. Individuals with d) metastatic disease despite a 532 significant concentration of RAI were defined as having positive uptake. Owing to the potential 533 heterogeneity of RR-PTC, patients in the RAI-refractory group were further categorized into three 534 subgroups: a) negative RAI uptake at the first RAI treatment with disease persistence (iDF), b) RAI uptake lost gradually after previous RAI treatments with disease persistence (iDG), and c) positive RAI 535 536 uptake but with disease persistence (ID). Tumor stage and the risk of recurrence were stratified using the American Joint Committee on Cancer (AJCC) staging system and the 2015 ATA guideline ^{8,63}. 537

538 Resected primary and metastatic lesions were preserved in formalin-fixed paraffin-embedded (FFPE) 539 tissue blocks at room temperature. A total of 168 FFPE samples were collected from the above 73 patients 540 (Figure 6C). The tissue types included primary tumors, synchronous cervical LNM, LNM after I-131 541 treatment, negative lymph nodes, and regional and distant metastatic lesions. Hematoxylin and eosin-542 stained slides from all samples were reviewed by two independent pathologists with expertise in thyroid pathology. The tissue blocks with the highest tumor purity in each patient were selected for subsequent 543 544 analysis. The borderlines of the tumor and adjacent tissues were carefully marked by expert pathologists.

545

546 4.3 Proteomic data acquisition and preprocessing

547 The FFPE samples were prepared for subsequent proteomic analysis as described previously 26,64 . The samples were allocated into ten batches. The tissues were subjected to a series of manipulations, 548 549 including dewaxing, rehydration and lysis, for peptide extraction and digestion via pressure cycling technology (PCT). Peptides were then quantified via a liquid chromatography (LC) system coupled with 550 551 a trapped ion mobility spectrometry mass spectrometer (MS). Data-independent acquisition (DIA) files 552 were acquired and then analyzed against a thyroid tissue specific spectral library ²⁶ using DIA-NN (v1.8.1) 553 ⁶⁵. Correlation analysis was conducted to assess the inter-batch and intra-batch stability of data 554 acquisition. The profile was then processed for protein filtration, imputation and ID conversion. A 555 detailed description of proteomic data acquisition, quality control and preprocessing can be found in the 556 supplementary methods.

557

558 4.4 Targeted next-generation sequencing (TNGS)

559 The primary lesions from 48 patients with PTC were subjected to molecular profiling via TNGS. The protocol was performed as described previously ⁶⁶. Briefly, DNA was extracted from FFPE tissue 560 561 sections using the QIAamp DNA FFPE Tissue Kit (Qiagen, Germany) following the manufacturer's

instructions. After amplification of targeted DNA fragments and removal of primers, the products were 562 563 purified using an Ion AmpliSeq Library Kit (Thermo Fisher Scientific, USA). The concentrations of samples were quantitated by a NanoDrop system (Thermo Fisher Scientific, USA). The quality of the 564 565 purified DNA was evaluated by 1% agarose gel electrophoresis. Severe degradation was detected in three 566 samples, which were excluded from further analysis.

567 The remaining 45 library products were sequenced via 150 bp paired-end runs on the NextSeq 500 568 platform (Illumina, Inc., USA). The medians of sequencing depth and coverage were 5136× and 98.7%, respectively. Sequencing data were aligned to a reference human genome dataset (hg19/GRCh37). 569 570 Subsequently, read mapping, quality control, variant calling and genotyping were performed following 571 the protocols of the OncoAim® Thyroid Cancer Multigene Assay Kit (Singlera Genomics, Inc., China). 572 Mutations and fusions were evaluated for 23 genes (Sup table S1). The minimum confidence threshold 573 for variant allele frequency was 5%. The ENSEMBL Variant Effect Predictor (v90) was used for variant 574 functional annotation. In addition, the gene variants were searched against the ClinVar database (v2020006) 67. Somatic gene variants were categorized for clinical significance based on the Catalogue 575 Of Somatic Mutations In Cancer database (COSMIC, v97) 68. 576

577

578 4.5 Bioinformatic analysis

579 DEPs were identified using a multiple linear regression algorithm and analysis of variance (ANOVA). 580 Differential expression analysis was conducted using the *limma* R package. Proteins with an absolute 581 FC > 1.414 and a P value < 0.05 were defined as DEPs. The dimension of the profile was reduced and 582 visualized using the PCA algorithm. ANOVA was used to identify proteins correlated with the severity 583 of RR-PTC. Proteins with statistical significance were clustered using the mfuzz R package. Proteins in 584 monotonically regulated clusters were regarded as DEPs.

585 Pathway enrichment analysis and gene ontology (GO) were conducted using four tools. GSEA was 586 conducted using GSEA software to evaluate potential pathways and molecular mechanisms. For GSVA, 587 ESs were calculated with the GSEA R package. Predefined gene sets were downloaded from the 588 Reactome and KEGG databases. The top enriched GO processes were identified via the Metascape web-589 based platform. Another network tool, IPA, identifies most significantly relevant pathways with the 590 overall activation or inhibition states based on DEPs.

591 Immune infiltration analysis was performed via the CIBERSORTX, ESTIMATE and single sample GSEA 592 (ssGSEA) algorithms. Several scores, including the TDS, ERK score and CYT, were calculated based on 593 the normalized protein profile. TIS and IIS were calculated using the Z score-standardized ssGSEA 594 matrix. BRAF-RAS score (BRS) was not calculated since no RAS-mutated samples were identified.

595 WGCNA was performed to cluster genes with high correlation and assess the correlation between 596 protein modules and gene alterations. Proteins in the modules that were highly associated with gene 597 mutations or fusions were selected. Least absolute shrinkage and selection operator (LASSO) regression, 598 random forest (RF), and support vector machine-recursive feature elimination (SVM-RFE) were used to 599 identify biomarker proteins based on selected proteins.

600 Several external datasets were used for the validation of our results (Sup Table S7). GSE151179 from 601 the GEO database included 52 samples derived from radioiodine-refractory and radioiodine-avid PTC

- 602 patients. This dataset was used to verify the results related to RAI refractoriness. The associations
- 603 between gene alterations and protein expression were assessed with the THCA (thyroid cancer) program

- 604 from TCGA and four additional datasets from the GEO database. The predictive performance of the
- 605 genes in the external datasets was evaluated with ROC curves.
- A detailed description of the bioinformatic analysis and references to methodological articles can be 606
- 607 found in the supplementary methods.
- 608

609 4.6 Statistical analysis

610 Quantitative variables were displayed as the means \pm standard deviations or medians \pm quartiles,

whereas qualitative variables were presented as numbers and ratios. The significant differences in the 611

612 quantitative variables were determined via two-tailed independent t test or Mann-Whitney U test, as

appropriate. The chi-square test was used to evaluate the differences in the distributions of qualitative 613 614 variables. When multiple groups were present, the z test with a Bonferroni correction was used to assess

- 615 the intergroup difference in every group. Statistical analysis was conducted using SPSS software (IBM,
- 616 US, v26).

618 Abbreviations

619 ANOVA, analysis of variance; ATA, American Thyroid Association; AUC, area under the curve (of ROC); 620 BRAF, B-Raf proto-oncogene, serine/threonine kinase; BRS, BRAF-RAS score; CC, correlation coefficient; COSMIC, the Catalogue Of Somatic Mutations In Cancer; CT, computed tomography; CYT, 621 622 immune cytolytic activity score; DEG, differentially expressed gene; DEP, differentially expressed protein; DIA, data-independent acquisition; DTC, differentiated thyroid cancer; ECP, eosinophil cationic 623 624 protein; ES, enrichment score; ERK, extracellular signal-regulated kinase; ETE, extrathyroidal extension; 625 FC, fold change: FFPE, formalin-fixed paraffin-embedded; F-18-FDG, 2-[¹⁸F]fluoro-2-deoxy-D-glucose; 626 GEO, the Gene Expression Omnibus database; GO, gene ontology; GS, gene significance; GSEA, gene 627 set enrichment analysis; GSVA, gene set variation analysis; HR, hazard ratio; ID, positive RAI uptake 628 and disease persistence; Id, RAI uptake positive and disease remission; iDF, negative RAI uptake at the 629 first time of RAI treatment with disease persistence; iDG, RAI uptake lost gradually after previous RAI 630 treatments with disease persistence; IIS, immune infiltration score; IP, inositol phosphate; IPA, ingenuine 631 pathway analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; KNN, K-nearest neighbor; 632 LASSO, least absolute shrinkage and selection operator; LC, liquid chromatography; LNM, lymph node 633 metastatic lesion; MAPK, mitogen-activated protein kinase; MET, MET proto-oncogene; MKI, multi-634 kinase inhibitor; MM, module membership; MS, mass spectrometry; MRI, magnetic resonance imaging; 635 NIS, sodium iodide symporter; PCA, principal component analysis; PCT, pressure cycling technology; 636 PET, positron emission tomography; RAI, radioactive iodine; RAIR, RAI-refractoriness; RF, random 637 forest; RFS, recurrence-free survival; RMA, robust multiarray average; ROC, receiver operating 638 characteristic; RR-PTC, radioactive iodine refractory papillary thyroid cancer; SPECT, single photon 639 emission computerized tomography; ssGSEA, single sample GSEA; SVM-RFE, support vector 640 machine-recursive feature elimination; TAK1, transforming growth factor- β activated kinase 1; TCGA, 641 The Cancer Genome Atlas Program; TERT, telomerase reverse transcriptase; TERTp, TERT promoter; 642 TDS, thyroid differentiation score; TIS, T cell infiltration score; TNF, tumor necrosis factor; TNGS, 643 targeted next-generation sequencing; TOM, topological overlap matrix; WBS, whole-body scanning; 644 WGCNA, weighted correlation network analysis. 645

646 Disclosure

647 Ethics approval statement

The Institutional Ethical Committee of the hospital reviewed and approved the study design (No. WDRY2021-K032). The requirement for obtaining informed consent from the involved patients was waived due to the retrospective nature of the study. The study was conducted in accordance with the Declaration of Helsinki.

652

653 Acknowledgement

654 We appreciate the great support by four expert pathologists, Dr. Xiaokang Ke, Dr. Jiacai Ren, Dr. 655 Xiaoyan Wu and Dr. Feng Guan, and the secretary of the Pathology Department, Mrs. Lingli Xia, at Renmin Hospital of Wuhan university. We give special thanks to Dr. Jun Liang in the Department of 656 657 Nuclear Medicine at Renmin Hospital of Wuhan University and Dr. Jie Tan in the Department of Breast 658 the Thyroid Surgery at Wuhan Union Hospital for their contribution and guidance in patient selection 659 and grouping. We thank Prof. Katherine Hoadley at the University of North Carolina at Chapel Hill for 660 her kind help in building a profile-based scoring system. We thank Dr. Zhou Liu from the Breast Tumor 661 Center of Sun Yat-Sen Memorial Hospital and Dr. Nancy Li from the Reactome HelpDesk for their timely 662 replies on two independent technical problems. We pay special thanks to authors who provided the 663 external expression profiles for validation in the present study.

664

665 Funding

This research was supported by grants from the Interdisciplinary Innovative Talents Foundation from Renmin Hospital of Wuhan University (JCRCFZ-2022-015), the Fundamental Research Funds for the Central Universities (2042019kf0229), the Natural Science Foundation of Hubei Province, China (2023AFB701), and the Thyroid Research Project for Young and Middle-aged Doctors from Bethune Charitable Foundation (JKM2022-B12). All these funds were given to Prof. Chuang Chen to cover the

- 671 costs during sample collection, TNGS, proteomics and other costs related to this academic research.
- 672

673 Conflicts of interest

All authors declare no competing interests.

676 Data and code availability

- 677 The proteomic data have been deposited in the iProX database with the project ID IPX0009103001.
- 678 Calculation files and additional data are available in the Mendeley database (DOI: 10.17632/yfpfvktrxn).
- No custom code was used in the current study.
- 680
- 681 Author contribution
- 682 Conceptualization: HQ Liu (supporting) and C Chen (lead).
- Data curation: HQ Liu, JX Wang, Y Zhou, PP Hu, L Li, DG Kong and ZL Xu (all equal).
- 684 Formal analysis: HQ Liu (lead), JX Wang (supporting), YT Sun (supporting) and Y Zhou (supporting).
- 685 Funding acquisition: C Chen (lead).
- 686 Investigation: HQ Liu (supporting), JX Wang (lead), D Yang (supporting), DG Kong (supporting) and
- 687 ZL Xu (supporting).
- 688 Methodology: HQ Liu (supporting), YT Sun (lead) and Y Zhou(supporting).
- 689 Project administration: HQ Liu, YT Sun, TN Guo and C Chen (all equal).
- 690 Resources: YT Sun, Y Zhu, TN Guo and C Chen (all equal).
- 691 Software: YT Sun (supporting), Y Zhou (lead), PP Hu (supporting) and L Li (supporting).
- 692 Supervision: YT Sun, Y Zhu, TN Guo and C Chen (all equal).
- 693 Validation: D Yang and Y Zhu (all equal).
- 694 Visualization: HQ Liu (supporting), D Yang (lead) and Y Zhu (supporting).
- 695 Writing original draft: HQ Liu (lead), JX Wang (supporting), YT Sun (supporting) and Y Zhou 696 (supporting).
- 697 Writing review & editing: D Yang (supporting), YT Sun (supporting), TN Guo (lead) and C Chen (lead).
- 698

All rights reserved. No reuse allowed without permission.

699 References

700 1 Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA: a cancer journal for 701 clinicians 74, 12-49, doi:10.3322/caac.21820 (2024). 702 Li, M. et al. Changing incidence and projections of thyroid cancer in mainland China, 1983-2 703 2032: evidence from Cancer Incidence in Five Continents. Cancer Causes & Control 32, 1095-704 1105, doi:10.1007/s10552-021-01458-6 (2021). 705 3 Pereira, M., Williams, V. L., Johnson, J. & Valderrabano, P. Thyroid Cancer Incidence Trends 706 in the United States: Association with Changes in Professional Guideline Recommendations. 707 Thyroid 30, 1132-1140, doi:10.1089/thy.2019.0415 (2020). 708 4 Miranda-Filho, A. et al. Thyroid cancer incidence trends by histology in 25 countries: a 709 population-based study. Lancet Diabetes & Endocrinology 9, 225-234, doi:10.1016/s2213-710 8587(21)00027-9 (2021). 711 5 Lim, H., Devesa, S. S., Sosa, J. A., Check, D. & Kitahara, C. M. Trends in Thyroid Cancer 712 Incidence and Mortality in the United States, 1974-2013. Jama-Journal of the American 713 Medical Association 317, 1338-1348, doi:10.1001/jama.2017.2719 (2017). 714 van Velsen, E. F. S. et al. Evaluating Disease-specific Survival Prediction of Risk Stratification 6 715 and TNM Systems in Differentiated Thyroid Cancer. Journal of Clinical Endocrinology & 716 Metabolism 108, E267-E274, doi:10.1210/clinem/dgac721 (2023). 717 7 Manzardo, O. A. et al. TNM 8th edition in thyroid cancer staging: is there an improvement in 718 predicting recurrence? Endocrine-Related Cancer 27, 325-336, doi:10.1530/erc-19-0412 719 (2020). 720 8 Haugen, B. R. et al. 2015 American Thyroid Association Management Guidelines for Adult 721 Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid 722 Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 723 Thyroid 26, 1-133, doi:10.1089/thy.2015.0020 (2016). 724 van Velsen, E. F. S. et al. Evaluating the 2015 American Thyroid Association Risk Stratification 9 725 System in High-Risk Papillary and Follicular Thyroid Cancer Patients. Thyroid 29, 1073-1079, 726 doi:10.1089/thy.2019.0053 (2019). 727 10 Nunes, K. S. et al. Risk factors associated with disease-specific mortality in papillary thyroid 728 cancer patients with distant metastases. Endocrine 75, 814-822, doi:10.1007/s12020-021-729 02901-z (2022). 730 Durante, C. et al. Long-term outcome of 444 patients with distant metastases from papillary and 11 731 follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. Journal of Clinical 732 Endocrinology & Metabolism 91, 2892-2899, doi:10.1210/jc.2005-2838 (2006). 733 Ciarallo, A. & Rivera, J. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 12 734 Update. American Journal of Roentgenology 215, 285-291, doi:10.2214/ajr.19.22626 (2020). 735 13 Sakulpisuti, C., Charoenphun, P. & Chamroonrat, W. Positron Emission Tomography 736 Radiopharmaceuticals in Differentiated Thyroid Cancer. Molecules 27, 4936, 737 doi:10.3390/molecules27154936 (2022). 738 14 Durante, C. et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in 739 iodine metabolism. Journal of Clinical Endocrinology & Metabolism 92, 2840-2843, 740 doi:10.1210/jc.2006-2707 (2007).

741	15	Riesco-Eizaguirre, G. et al. The BRAF V600E Oncogene Induces Transforming Growth Factor
742		β Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in
743		Thyroid Cancer. <i>Cancer Research</i> 69 , 8317-8325, doi:10.1158/0008-5472.Can-09-1248 (2009).
744	16	Liu, J. et al. The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly
745		Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer. Journal of Nuclear
746		<i>Medicine</i> 61 , 177-182, doi:10.2967/jnumed.119.227652 (2020).
747	17	Cao, J. <i>et al.</i> The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor
748	1,	curative effect of radioiodine therapy in papillary thyroid cancer. <i>European Journal of Nuclear</i>
749		Medicine and Molecular Imaging 49, 3470-3481, doi:10.1007/s00259-022-05820-x (2022).
750	18	Groener, J. B. <i>et al.</i> BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary
751	10	Thyroid Cancer. <i>Hormone and Metabolic Research</i> 51 , 69-75, doi:10.1055/a-0765-9078 (2019).
752	19	Yang, X. <i>et al.</i> TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant
752 753	19	-
		Metastatic Differentiated Thyroid Cancer. Journal of Nuclear Medicine 58, 258-265, doi:10.2067/inumed.116.180240.(2017)
754 755	20	doi:10.2967/jnumed.116.180240 (2017).
755	20	Feng, F. <i>et al.</i> A nonpump function of sodium iodide symporter in thyroid cancer via cross-talk
756		with PTEN signaling. <i>Cancer Research</i> 78 , 6121-6133, doi:10.1158/0008-5472.Can-18-1954
757	0.1	
758	21	Dohán, O., Baloch, Z., Bánrévi, Z., Livolsi, V. & Carrasco, N. Predominant intracellular
759		overexpression of the Na+/I- symporter (NIS) in a large sampling of thyroid cancer cases.
760		Journal of Clinical Endocrinology & Metabolism 86, 2697-2700, doi:10.1210/jc.86.6.2697
761		(2001).
762	22	Marsee, D. K. et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein,
763		increases radioiodide accumulation in thyroid cells. Journal of Biological Chemistry 279,
764		43990-43997, doi:10.1074/jbc.M407503200 (2004).
765	23	Paron, I. et al. Nuclear localization of Galectin-3 in transformed thyroid cells: a role in
766		transcriptional regulation. Biochemical and Biophysical Research Communications 302, 545-
767		553, doi:10.1016/s0006-291x(03)00151-7 (2003).
768	24	Huang, D. et al. Proteotypic Differences of Follicular-Patterned Thyroid Neoplasms. Frontiers
769		in endocrinology 13, 854611, doi:10.3389/fendo.2022.854611 (2022).
770	25	Qu, N. et al. Integrated proteogenomic and metabolomic characterization of papillary thyroid
771		cancer with different recurrence risks. Nature Communications 15, 3175, doi:10.1038/s41467-
772		024-47581-1 (2024).
773	26	Sun, Y. et al. Stratification of follicular thyroid tumours using data-independent acquisition
774		proteomics and a comprehensive thyroid tissue spectral library. Molecular oncology 16, 1611-
775		1624, doi:10.1002/1878-0261.13198 (2022).
776	27	Shi, X. et al. Integrated proteogenomic characterization of medullary thyroid carcinoma. Cell
777		discovery 8, 120, doi:10.1038/s41421-022-00479-y (2022).
778	28	Colombo, C. et al. The molecular and gene/miRNA expression profiles of radioiodine resistant
779		papillary thyroid cancer. Journal of Experimental & Clinical Cancer Research 39, 245,
780		doi:10.1186/s13046-020-01757-x (2020).
781	29	Xing, M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature Reviews Cancer
782		13, 184-199, doi:10.1038/nrc3431 (2013).
783	30	Arturi, F. et al. Iodide symporter gene expression in human thyroid tumors. Journal of Clinical
784		Endocrinology & Metabolism 83, 2493-2496, doi:10.1210/jc.83.7.2493 (1998).

785 786	31	Anekpuritanang, T. et al. The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAFV600E Mutation. Oncotargets
787		and Therapy 14, 3959-3969, doi:10.2147/ott.S308910 (2021).
788	32	Zhang, R. et al. Association between sodium iodide symporter and differentiated Thyroid cancer:
789		a meta-analysis of 9 studies. International Journal of Clinical and Experimental Medicine 8,
790		17986-17994 (2015).
791	33	Braga-Basaria, M. & Ringel, M. D. Beyond radioiodine: A review of potential new therapeutic
792		approaches for thyroid cancer. Journal of Clinical Endocrinology & Metabolism 88, 1947-1960,
793		doi:10.1210/jc.2002-021863 (2003).
794	34	Agrawal, N. et al. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell
795		159, 676-690, doi:10.1016/j.cell.2014.09.050 (2014).
796	35	Xing, M. et al. Association Between BRAF V600E Mutation and Recurrence of Papillary
797		Thyroid Cancer. Journal of Clinical Oncology 33, 42-U79, doi:10.1200/jco.2014.56.8253
798		(2015).
799	36	Luo, Y. et al. Clinical, Pathological, and Molecular Characteristics Correlating to the
800		Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review
801		and Meta-Analysis. Frontiers in Oncology 10, 549882, doi:10.3389/fonc.2020.549882 (2020).
802	37	Zhang, Z., Liu, D., Murugan, A. K., Liu, Z. & Xing, M. Histone deacetylation of NIS promoter
803		underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocrine-Related Cancer
804		21 , 161-173, doi:10.1530/erc-13-0399 (2014).
805	38	Mu, Z. et al. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic
806		Thyroid Cancer. Journal of Clinical Endocrinology & Metabolism 109, 1231-1240,
807		doi:10.1210/clinem/dgad697 (2024).
808	39	Collina, F. et al. AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine
809		Refractory Thyroid Cancer. Cancers 11, 785, doi:10.3390/cancers11060785 (2019).
810	40	Meng, Z. et al. TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts
811		absent or lower (131)i uptake in metastases. Iubmb Life 71, 1030-1040, doi:10.1002/iub.2056
812		(2019).
813	41	Jung, C. K. et al. Risk Stratification Using a Novel Genetic Classifier Including PLEKHS1
814		Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis. Thyroid 30,
815		1589-1600, doi:10.1089/thy.2019.0459 (2020).
816	42	Liu, R. et al. Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter
817		Mutations in Papillary Thyroid Cancer Genetic Duet of BRAF and TERT Promoter Mutations
818		in Thyroid Cancer Mortality. Jama Oncology 3, 202-208, doi:10.1001/jamaoncol.2016.3288
819		(2017).
820	43	Yu, P. et al. TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and
821		progression by regulating ribosome biogenesis. Science Advances 9, eadg7125,
822		doi:10.1126/sciadv.adg7125 (2023).
823	44	Ju, G. et al. Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic
824		Differentiated Thyroid Cancer. Journal of Clinical Endocrinology & Metabolism 109, 505-515,
825		doi:10.1210/clinem/dgad500 (2024).
826	45	Arai, S. et al. In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-
827		RET. Oncotarget 8, 73766-73773, doi:10.18632/oncotarget.17900 (2017).
828	46	Paratala, B. S. et al. RET rearrangements are actionable alterations in breast cancer. Nature

829		Communications 9, 4821, doi:10.1038/s41467-018-07341-4 (2018).
830	47	Groussin, L. <i>et al.</i> Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid
831	.,	Cancer. <i>Thyroid</i> 31 , 1603-1604, doi:10.1089/thy.2021.0144 (2021).
832	48	Lee, Y. A. <i>et al.</i> NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a
833	40	tumor response and radioiodine uptake. Journal of Clinical Investigation 131, e144847,
834		doi:10.1172/jci144847 (2021).
835	49	Nikitski, A. V. <i>et al.</i> Can TP53-mutant follicular adenoma be a precursor of anaplastic thyroid
836	т <i>у</i>	carcinoma? Endocrine-Related Cancer 28, 621-630, doi:10.1530/erc-21-0095 (2021).
837	50	Fu, H. <i>et al.</i> MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary
	30	
838		Thyroid Cancer Cells Harboring BRAFV600E : An In Vitro. <i>Molecular Therapy-Oncolytics</i> 12 , 225-245. doi:10.1016/j.cmtz.2010.01.007.(2010)
839	51	235-245, doi:10.1016/j.omto.2019.01.007 (2019).
840	51	Rothenberg, S. M., McFadden, D. G., Palmer, E. L., Daniels, G. H. & Wirth, L. J.
841		Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid
842		Cancer with Dabrafenib. <i>Clinical Cancer Research</i> 21 , 1028-1035, doi:10.1158/1078-0432.Ccr-
843		14-2915 (2015).
844	52	Zhang, C. <i>et al.</i> Inhibitory effects of siRNA targeting silencing TAK1 gene on proliferation and
845		migration of thyroid cancer cells and p38 MAPK signaling pathway. <i>Journal of Jilin University</i> .
846		<i>Medicine edition</i> 47 , 110-117 (2021).
847	53	Gheorghe, D. C., Stanciu, M. M., Zamfirescu, A. & Stanciu, A. E. TNF-α May Exert Different
848		Antitumor Effects in Response to Radioactive Iodine Therapy in Papillary Thyroid Cancer
849		with/without Autoimmune Thyroiditis. Cancers 13, 3609, doi:10.3390/cancers13143609 (2021).
850	54	Yen, MC. et al. S100B expression in breast cancer as a predictive marker for cancer metastasis.
851		International Journal of Oncology 52, 433-440, doi:10.3892/ijo.2017.4226 (2018).
852	55	Wang, X. et al. A Functional Insertion/Deletion Polymorphism in the Promoter Region of the
853		NFKB1 Gene Increases the Risk of Papillary Thyroid Carcinoma. Genetic Testing and
854		Molecular Biomarkers 19, 167-171, doi:10.1089/gtmb.2014.0271 (2015).
855	56	Sponziello, M. et al. Fibronectin-1 expression is increased in aggressive thyroid cancer and
856		favors the migration and invasion of cancer cells. <i>Molecular and Cellular Endocrinology</i> 431 ,
857		123-132, doi:10.1016/j.mce.2016.05.007 (2016).
858	57	Chen, X., Zheng, J., Zhang, A. & You, Z. Increased FN1 expression correlates to poor prognosis,
859		BRAF mutation and immune infiltrates in papillary thyroid cancer. Chinese Journal of
860		Immunology 37 , 1841-1847 (2021).
861	58	Sabra, M. M. et al. Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers
862		With Radioiodine-Avid Distant Metastases. Journal of Clinical Endocrinology & Metabolism
863		98, E829-E836, doi:10.1210/jc.2012-3933 (2013).
864	59	Shobab, L. et al. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine
865		Refractory Differentiated Thyroid Cancer. Thyroid 29, 1262-1268, doi:10.1089/thy.2019.0075
866		(2019).
867	60	Song, HJ., Xue, YL., Qiu, ZL. & Luo, QY. Comparative serum proteomic analysis
868		identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-
869		1311-avid lung metastases. Nuclear Medicine Communications 34, 1196-1203,
870		doi:10.1097/mnm.00000000000001 (2013).
871	61	Li, Y. et al. Proteomic analysis of radioiodine-refractory differentiated thyroid cancer identifies
872		CHI3L1 upregulation in association with dysfunction of the sodium-iodine symporter.

873		Oncology Letters 25, 36, doi:10.3892/ol.2022.13622 (2023).
874	62	World Med, A. World Medical Association Declaration of Helsinki Ethical Principles for
875		Medical Research Involving Human Subjects. Jama-Journal of the American Medical
876		Association 310, 2191-2194, doi:10.1001/jama.2013.281053 (2013).
877	63	Perrier, N. D., Brierley, J. D. & Tuttle, R. M. Differentiated and Anaplastic Thyroid Carcinoma:
878		Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging
879		Manual. CA: a cancer journal for clinicians 68, 56-63, doi:10.3322/caac.21439 (2018).
880	64	Cai, X. et al. High-throughput proteomic sample preparation using pressure cycling technology.
881		Nature Protocols 17, 2307-2325, doi:10.1038/s41596-022-00727-1 (2022).
882	65	Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural
883		networks and interference correction enable deep proteome coverage in high throughput. Nature
884		Methods 17, 41-+, doi:10.1038/s41592-019-0638-x (2020).
885	66	Xiong, Y. et al. Application of biomarkers in the diagnosis of uncertain samples of core needle
886		biopsy of thyroid nodules. Virchows Archiv 479, 961-974, doi:10.1007/s00428-021-03161-y
887		(2021).
888	67	Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants.
889		Nucleic Acids Research 44, D862-D868, doi:10.1093/nar/gkv1222 (2016).
890	68	Tate, J. G. et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids
891		Research 47, D941-D947, doi:10.1093/nar/gky1015 (2019).
892		
893		

894 Tables, figures and supplementary materials

895 Tables

Clinicopathological	All patients (48)	RR-PTC (37)	Control (11)	P value
features				
Age at diagnosis				
Years	$\textbf{38.4} \pm \textbf{12.69}$	39.2 ± 13.29	35.6 ± 10.49	0.421
≥55 y	5 (10.4)	5 (13.5)	0 (0)	0.576
Female sex	28 (58.3)	20 (54.1)	8 (72.7)	0.319
Tumor diagnosis				0.302
Incidental	22 (45.8)	15 (40.5)	7 (63.6)	
Symptomatic	26 (54.2)	22 (59.5)	4 (36.4)	
Smoking or alcohol	9 (18.8)	8 (21.6)	1 (9.1)	0.662
BMI (kg/m ²)	24.1 ± 5.36	24.6 ± 5.75	22.5 ± 3.47	0.261
Hashimoto's thyroiditis	1 (2.1)	1 (2.7)	0 (0)	1.000
Nodular goiter	10 (20.8)	7 (18.9)	3 (27.3)	0.675
Histological subtypes ^a				
cPTC	39 (81.3)	29 (78.4)	10 (90.9)	0.662
fvPTC	13 (27.1)	12 (32.4)	1 (9.1)	0.246
tcv/svPTC	6 (12.5)	5 (13.5)	1 (9.1)	1.000
Tumor size (cm)	2.1 ± 1.40	2.1 ± 1.38	2.1 ± 1.40	0.996
Multifocality	36 (75.0)	28 (75.7)	8 (72.7)	1.000
Bilateral lesion	27 (56.3)	20 (54.1)	7 (63.6)	0.733
ETE	37 (77.1)	31 (83.8)	6 (54.5)	0.095
TNM				
T1	7 (14.6)	3 (8.1)	4 (36.4)	0.039 *
T2-4	41 (85.4)	34 (91.9)	7 (63.6)	
N0	3 (6.3)	3 (8.1)	0 (0)	1.000
N1	45 (93.8)	34 (91.9)	11 (100)	
M0	26 (54.2)	16 (43.2)	10 (90.9)	0.006 *
M1	22 (45.8)	21 (56.8)	1 (9.1)	
AJCC stage				0.001 *
Ι	22 (45.8)	12 (32.4)	10 (90.9)	
II/III/IV	26 (54.2)	25 (67.6)	1 (9.1)	
ATA risk stratification				1.000
Low	0 (0)	0 (0)	0 (0)	
Intermediate/high	48 (100)	37 (100)	11 (100)	
Cumulative dose of RAI	370 (220, 570)	430 (220, 430)	220 (220, 250)	0.002 *
(mCi)				
Follow up				0.313

Alive	42 (87.5)	31 (83.8)	11 (100)	
Dead	6 (12.5)	6 (16.2)	0 (0)	

Note: Quantitative variables were displayed as mean ± standard deviation, whereas qualitative variables 897

898 were displayed as number (ratio). The cumulative dose of RAI was presented as medians (quartiles) due

899 to inconformity to Gaussian distribution.

900 ^a Multiple tumors in one patient may exhibit different histopathological types. The diameters of the

901 largest tumor were measured when multiple lesions existed.

* *P* < 0.05, ** *P* < 0.01. 902

Abbreviations: AJCC, American Joint Committee on Cancer; ATA, American Thyroid Association; BMI, 903

body mass index; cPTC, classic papillary thyroid cancer; ETE, extrathyroidal extension; fvPTC, 904

905 follicular variant of papillary thyroid cancer; RAI, radioactive iodine; svPTC, solid variant of papillary

thyroid cancer; tcvPTC, tall cell variant of papillary thyroid cancer. 906

Comparison	BRAF	RET	TERTp	TP53	Fusion ^a	RET fusion	NCOA4-
							RET
RR-PTC vs.							
Control							
RR-PTC (35)	19 (54.3)	0 (0)	6 (17.1)	1 (2.9)	10 (28.6)	8 (22.9)	7 (20.0)
Control (10)	6 (60.0)	1 (10.0)	0 (0)	1 (10.0)	4 (40.0)	2 (20.0)	1 (10.0)
P value	1.000	0.222	0.312	0.399	0.700	1.000	0.661
Subgroups							
ID (9)	1 (11.1) *	0 (0)	1 (11.1)	1 (11.1)	4 (44.4)	4 (44.4)	4 (44.4)
iDF (9)	6 (66.7)	0 (0)	3 (33.3) *	0 (0)	1 (11.1)	1 (11.1)	0 (0)
iDG (17)	12 (70.6)	0 (0)	2 (11.8)	0 (0)	5 (29.4)	3 (17.6)	3 (17.6)
Id (10)	6 (60.0)	1 (10.0)	0 (0)	1 (10.0)	4 (40.0)	2 (20.0)	1 (10.0)
P value	0.026 *	0.311	0.193	0.411	0.421	0.327	0.081
I-131 uptake							
Negative (26)	18 (69.2)	0 (0)	5 (19.2)	0 (0)	6 (23.1)	4 (15.4)	3 (11.5)
Positive (19)	7 (36.8)	1 (5.3)	1 (5.3)	2 (10.5)	8 (42.1)	6 (31.6)	5 (26.3)
P value	0.039 *	0.422	0.222	0.173	0.206	0.281	0.253


908 Table 2. The comparison of gene mutations and fusions in RAI-refractory and RAI-sensitive PTC

909 * P < 0.05. Bold font indicated statistical significance revealed by z test.

910 ^a Detected gene fusions included ETV6-NTRK3 in three samples, one STRN-ALK, two CCDC6-RET and

eight NCOA4-RET. The latter two fusions were collectively called RET fusion. 911

913 Figures



- 915 Figure 1. Proteomic overview of RAI-refractory and RAI-sensitive PTC samples. (A-C) Dimension reduction visualization of the analyzed PTC samples. The samples were labeled according to
- 916 their response to I-131 treatment (refractory or sensitive), subgroup (iDF, iDG, ID or Id) and BRAF mutation status. Three samples whose quality control for sequencing failed were not included
- 917 in Figure C. (D) Differential expression analysis of samples in the RR-PTC and control groups. Unadjusted P values < 0.05 and absolute FC > 1.414 were defined as thresholds for DEPs. (E)
- 918 Overview of the proteomic profiles. Z scores of the DEPs were calculated. (F) Correlation of scores and groups. Error bar denoted 95% CI. The TDS was lower in the RR-PTC group (-0.17 ±
- 919 $0.562 \text{ vs. } 0.03 \pm 0.512, P = 0.288$). Conversely, the ERK score was greater in the RR-PTC group ($0.03 \pm 0.317 \text{ vs. } -0.10 \pm 0.297, P = 0.215$). The means and SDs are presented with boxes and
- 920 error bars.
- 921 Abbreviations: age at D, age at diagnosis; DM, distant metastasis; ETE, extrathyroidal extension; LNM, lymph node metastasis.





Figure 2. Differential expression analysis of the ID and iDF groups. (A) PCA plot of the two groups. (B) Differential expression analysis of samples in the two groups. Unadjusted *P* values < 0.05 and absolute FC > 1.414 were defined as thresholds for DEPs. (C) Correlations of scores and groups. Error bar denoted 95% CI. The TDS was greater in the ID group (0.03 ± 0.599 vs. -


- 0.20 ± 0.454 , P = 0.356), while the ERK score was greater in the iDF group (-0.07 ± 0.345 vs. 0.07 ± 0.300 , P = 0.386). (D) Expression profiles of 145 DEPs. (E&F) GSEA based on the KEGG
- 926 and Reactome databases. Sixteen pathways are presented in the plot.



928

Figure 3. Expression of selected genes according to the enriched pathways identified in the ID vs. iDF and ID vs. Id comparisons. (A&D) Dysregulated pathways identified in the ID vs. iDF and ID vs. Id comparisons. The *P* value threshold was 0.05. No threshold was set for fold change. (B) The ten most significantly enriched pathways and the thirteen selected pathways. (C) The selected proteins from the thirteen selected pathways. The threshold of absolute fold change was > 1.2. (E) The eight significantly enriched pathways and thirteen selected pathways. (F) The selected proteins from the thirteen selected pathways. The TNF signaling pathway and the TAK1-related pathways were combined in a single plot since the proteins strongly overlapped. * P < 0.05, ** P < 0.01.


- ^a The pathway "MET activates PTPN1" was also selected for subsequent identification of proteins.
- 935 ^{b, c} Involved in the selected pathways "glutathione synthesis and recycling" and "MET activates PTPN11", respectively.
- ^d Both CDK1 and MAP2K1 participate in the pathways "MAPK3 (ERK1) activation" and "RAF-independent MAPK1/3 activation", and MAP2K1 is also a participant in "prolonged ERK
 activation events".
- 938 ° TAB2 and TAB1 are involved in both MAPK and TAK1-associated pathways, while CD14 participates in TAK1-associated pathways.
- 939 ^f Molecules in these figures might participate in several pathways. The associations of molecules and pathways are provided in Sup table S5.




940

Figure 4. Differential expression analysis of the ID and Id groups. (A) PCA plot of the two groups. (B) Differential expression analysis of samples in the two groups. Unadjusted *P* values < 0.05and absolute FC > 1.414 were defined as thresholds for DEPs. (C) Correlations of scores and groups. Error bar denoted 95% CI. No significant difference was found in the TDS (0.03 ± 0.599

- 943 vs. 0.03 ± 0.512 , P = 0.985) or ERK score (-0.07 ± 0.345 vs. -0.10 ± 0.297 , P = 0.796). (D) Expression profiles of 125 DEPs. (E&F) GSEA based on the KEGG and Reactome databases. Sixteen
- 944 pathways are presented in the plot.



- Figure 5. Gene variants and weighted gene co-expression network analysis. (A) Gene variance landscape. (B) Correlations of gene modules and gene phenotypes. The cells were divided into
- 947 upper left (correlation coefficient) and lower right (P value) parts. (C) The intersection of LASSO-, RF- and SVM-RFE-identified biomarkers for BRAF, and TERTp mutations, gene fusions and
- 948 NCOA4-RET fusion. (D) Validation of six genes in the TCGA-THCA cohort and merged GEO cohort. PTCD1 was not detected in the merged GEO dataset.
- a The low number of *TERTp*-positive samples (n = 6) prevented model construction and error analysis for *TERTp* mutations via the SVM algorithm. The first ten proteins with the top average
- 950 rank were processed for biomarker identification.



- 952 Figure 6. (A) Flow chart of patient and sample selection. Strict criteria were followed to identify patients with RAI-refractory or RAI-sensitive thyroid cancers. Individuals with insufficient
- 953 radiological evidence were also excluded from the second round of selection. A total of 73 patients (in the dashed box) were revealed to have regional or distant metastatic lesions with solid
- 954 evidence. The FFPE tissues were collected for subsequent proteomic analysis and/or targeted deep sequencing. Notably, 25 patients were excluded from this study due to a lack of primary lesions
- 955 or not having PTC. (B) Grouping of included patients. Three samples are shown here for the Id, ID and iD groups. The first patient belonged to the Id group. Her or his lung metastases, which
- 956 were confirmed by I-131 WBS and chest CT, were eliminated by two I-131 treatments. The second patient was included in the ID group. She or he received total thyroidectomy but her or his
- 957 cervical regional metastatic lesion progressed during the four rounds of I-131 treatment. The first and second I-131 WBSs of the third patient revealed no positive focus. However, PET/CT during
- 958 the same period revealed several suspicious pulmonary nodules (red arrow), which were confirmed to be metastases by subsequent surgery and histopathology. (C) Information on the collected
- 959 FFPE samples. The protein profiles of 168 samples were evaluated in 10 batches. The sample types included primary lesions, synchronous and post I-131 cervical LNM, negative cervical lymph
- 960 node and regional or distant metastatic lesions. Notably, the regional metastatic lesions were tumors near the primary site, such as the esophagus, trachea and cervical skin. LNM was not included
- 961 in regional metastatic lesions. In addition, forty-eight primary tumors were examined via targeted deep sequencing.
- ^a The primary lesion of one patient was neither resected in our center nor examined to be PTC.
- 963

964 Supplementary materials

- 965 Supplementary methods
- 966 Supplementary tables 1-7
- Supplementary figure 1-12 967
- 968 References
- 969